Avexitide (Exendin 9-39) is an antagonist of glucagon-like peptide-1 (GLP-1) receptor, and also acts as an inhibitor of glucosedependent insulinotropic polypeptide (GIP)-receptor binding. Avexitide (Exendin 9-39) is a competitive inhibitor of exendin-3 and exendin-4. It also prevents the production of cAMP by GIP. GLP-1, along with GIP, acts as a physiological incretin. Avexitide (Exendin 9-39) has been used to study its effect on basal microvascular permeability.
Amino Acid Sequence
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||Water 30 mg/mL|
|Storage||-20°C, dry, sealed|
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Kristopher C Dozier, et al. Peptides. 2009 Sep;30(9):1735-41. PMID: 19560500.
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin
V A Gault, et al. Diabetologia. 2003 Feb;46(2):222-30. PMID: 12627321.
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39
C M Edwards, et al. Diabetes. 1999 Jan;48(1):86-93. PMID: 9892226.
|Related Glucagon Receptor Products|
PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R) agonist.
Teduglutide is a glucagon-like peptide-2 (GLP- 2) receptor agonist used for the treatment of short-bowel syndrome.
NNC0640 is a potent, negative allosteric modulator (NAM) of human G-protein-coupled glucagon receptor (GCGR) with IC50 of 69.2 nM.
Cotadutide acetate is a potent peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptor, with EC50 values of 6.9 pM and 10.2 pM, respectively.
Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.